Here are 1-2 analogies to describe Stryker (SYK):

• Essentially Johnson & Johnson, but focused entirely on medical devices like joint replacements, surgical equipment, and patient care systems.
• The Caterpillar of the medical world, supplying hospitals with essential surgical tools, implants (like joint replacements), and equipment.

• Orthopaedic Implants: Provides implants for joint replacement (hips, knees, shoulders) and trauma care, designed to restore mobility and function.
• Surgical Technologies and Endoscopy: Offers surgical instruments, power tools, operating room integration, navigation systems, and endoscopic visualization solutions for various surgical specialties.
• Neurotechnology and Spine Products: Develops and manufactures devices for neurovascular intervention, craniofacial reconstruction, ENT surgery, and spinal fusion and stabilization.
• Medical and Patient Handling Equipment: Supplies hospital beds, stretchers, patient transport solutions, and emergency medical equipment for patient care and safety.
• Robotic-Assisted Surgery: Features integrated systems like the Mako System that provide pre-operative planning and robotic-assisted execution for increased precision in orthopaedic surgeries.

Stryker (SYK) Major Customers

Stryker (SYK) is a medical technology company that designs, manufactures, and markets medical devices. As such, it sells primarily to other companies within the healthcare sector (B2B model), rather than directly to individuals.

While Stryker does not publicly disclose its specific "major customer companies" due to the highly diversified nature of its sales across thousands of healthcare providers globally, its customer base consists primarily of large hospital systems, ambulatory surgical centers (ASCs), and other healthcare facilities and medical professionals. Stryker's products are essential for various surgical procedures, patient care, and hospital operations.

Examples of prominent, publicly traded healthcare systems in the United States that are major purchasers of medical devices, including those offered by Stryker, for their extensive networks of hospitals and healthcare facilities, include:

• HCA Healthcare (Symbol: HCA)
• Tenet Healthcare Corporation (Symbol: THC)
• Universal Health Services, Inc. (Symbol: UHS)
• Community Health Systems, Inc. (Symbol: CYH)

These companies represent significant players in the healthcare provider market and are typical customers for medical device manufacturers like Stryker.

null

Kevin A. Lobo, Chairman and Chief Executive Officer

Kevin Lobo joined Stryker in 2011 as Group President of Orthopaedics. He was appointed President and Chief Executive Officer in October 2012 and assumed the role of Chairman of the Board in July 2014. Prior to joining Stryker, Mr. Lobo held senior leadership roles at Johnson & Johnson, including President of Ethicon Endo-Surgery, Inc., and Chief Financial Officer at McNeil Consumer Healthcare. His career also includes finance positions with KPMG, Unilever Canada, and Kraft Canada, encompassing executive positions in general management and finance across multiple industries.

Preston W. Wells, Vice President and Chief Financial Officer

Preston Wells will assume the role of Vice President and Chief Financial Officer effective April 1, 2025. He joined Stryker in 2015, beginning his career in the Spine Division where he led sales finance and sales operations. Subsequently, he led Financial Planning and Analysis and Investor Relations for the company. Most recently, he served as Vice President, Group Chief Financial Officer for Stryker's Orthopaedics and Spine Group. Before joining Stryker, Mr. Wells accumulated 17 years of experience in senior accounting and financial management roles at global organizations, including serving as CFO at Dialight Corporation and holding various financial leadership positions at Johnson & Johnson.

Viju S. Menon, Group President, Global Quality and Operations

Viju Menon was named Group President, Global Quality and Operations in April 2018. In this role, he is responsible for global operations, including manufacturing, direct procurement, regulatory affairs, quality assurance, sustainability, integrated business planning, logistics, and advanced operations such as additive manufacturing technology development. Prior to joining Stryker, Mr. Menon served as Chief Supply Chain Officer and Senior Vice President at Verizon. Before his tenure at Verizon, he held key leadership roles at Intel Corporation in technology, supply chain, and manufacturing operations.

J. Andrew Pierce, Group President, MedSurg and Neurotechnology

Andy Pierce became Group President, MedSurg and Neurotechnology in August 2019. He oversees Stryker's Endoscopy, Inari, Instruments, Medical, and Neurovascular Divisions, as well as the Asia Pacific Region, Customer Solutions Business, and Enterprise Strategy Function. Mr. Pierce joined Stryker in 1996 and has held various marketing, sales, and product management roles, including within the Instruments and Craniomaxillofacial (CMF) Divisions, eventually moving into leadership positions within the CMF Business. In 2008, he was promoted to Vice President and General Manager of CMF, and in 2013, he became President of the Endoscopy Division.

Spencer S. Stiles, Group President, Orthopaedics and Spine

Spencer Stiles became Group President, Orthopaedics and Spine in August 2019. In this role, he oversees the Joint Replacement, Trauma & Extremities, and Spine businesses, along with the Digital, Robotics, and Enabling Technologies organization. He is also directly responsible for Europe, Middle East, Africa, Latin America, and Canada, as well as Stryker's enterprise Mergers and Acquisitions function. Mr. Stiles began his career with Stryker in 1999 within the Endoscopy business and has held various sales, marketing, and general management roles across the Endoscopy, Spine, and Instruments divisions. He served as General Manager of the Communications business unit, President of Spine, and President of Instruments.

Key Risks to Stryker (SYK)

1. Regulatory and Legal Risks: Stryker operates in a highly regulated industry and is subject to extensive governmental oversight from bodies such as the FDA, state governments, and international authorities concerning the classification, manufacturing, labeling, marketing, and sale of its products. Changes in these evolving regulations, the costly and time-consuming process of obtaining necessary clearances and approvals, and the potential for product recalls pose significant business challenges. Furthermore, the company faces legal proceedings related to product liability claims, patent infringements, and investigations into potential violations of acts like the Foreign Corrupt Practices Act (FCPA), which could result in substantial financial penalties and reputational damage.
2. Supply Chain Disruptions and Cost Pressures: Stryker is vulnerable to disruptions across its global supply chain, including the availability of raw materials and components, which can adversely affect manufacturing and timely product delivery. The reliance on single suppliers for certain raw materials exacerbates this risk. The company also faces ongoing inflationary pressures, increased energy and transportation costs, and the impact of tariffs, all of which contribute to higher operational expenses and pressure on profit margins.
3. Intense Competition and Pricing Pressure: The medical technology sector is characterized by intense competition from major global and local companies, including Medtronic, Johnson & Johnson, and Zimmer Biomet. This competitive landscape leads to pricing pressures, especially in key segments like orthopedic implants and robotic-assisted surgery. Sustained success requires continuous innovation and significant investment in research and development, while Group Purchasing Organizations (GPOs) further exert pressure by negotiating substantial discounts on medical device purchases.

• Advances in regenerative medicine and biological therapies that could reduce or eliminate the need for traditional surgical interventions (e.g., joint replacements) by repairing or regenerating damaged tissues and organs.
• Increasing penetration and integration of large technology companies (e.g., Amazon, Apple, Google) into healthcare delivery, patient pathways, and data management, potentially disrupting traditional medical device sales channels, influencing treatment decisions, or introducing new, vertically integrated care models.

Stryker (SYK) operates in three main business segments: Orthopaedics, MedSurg (Medical and Surgical), and Neurotechnology and Spine. The addressable markets for these segments are sized as follows:

Orthopaedics

The global orthopedic devices market, which includes joint replacement systems, trauma, and extremities products, was valued at approximately USD 60.4 billion in 2023. It is projected to grow to USD 80.8 billion by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 4.3% from 2024 to 2030. Other estimates place the global market at USD 61.9 billion in 2024, with projections reaching USD 86 billion by 2032. North America held the largest share of the orthopedic devices market in 2024, accounting for 47% of the revenue. Specifically, the worldwide knee and hip market generated $17.4 billion in sales in 2024, and the worldwide extremities market generated $6 billion in sales in 2024.

MedSurg (Medical and Surgical)

Stryker's MedSurg segment includes surgical equipment, patient handling, and emergency medical equipment. The global surgical equipment market was estimated at USD 18.37 billion in 2024 and is projected to reach USD 31.58 billion by 2030, growing at a CAGR of 9.54% from 2025 to 2030. Another estimate indicates the global surgical equipment market size reached USD 19.9 billion in 2024 and is expected to reach USD 34.0 billion by 2033, with a CAGR of 6.05% from 2025 to 2033. The global market for surgical equipment and technologies was valued at $37.6 billion in 2023 and is expected to grow to $40.0 billion in 2024, reaching approximately $56.6 billion by 2029 at a CAGR of 7.2% from 2024 to 2029. North America dominated the surgical equipment market in 2024 with a 40.3% share.

Neurotechnology and Spine

The Neurotechnology and Spine segment comprises neurovascular products, neurosurgical and neurovascular devices, and spinal devices. The global neurotechnology market was valued at approximately USD 15.35 billion in 2024, increasing to USD 17.38 billion in 2025, and is projected to reach around USD 53.18 billion by 2034, expanding at a CAGR of 13.23% between 2025 and 2034. The U.S. neurotechnology market alone was valued at USD 3.86 billion in 2024 and is estimated to reach USD 13.60 billion by 2034. In 2024, North America was the dominant regional market for neurotechnology. Although Stryker sold its U.S. spinal implants business (which had $707 million in sales in 2024) in early 2025, it retains its interventional spine portfolio and robotic technologies like Mako Spine. The global spine devices market is expected to grow at a CAGR of 3.9% from 2024 to 2029. The total addressable market (TAM) for neurovascular products is estimated at $4 billion globally, with a High Single-Digit CAGR through 2026. Additionally, Stryker identifies mechanical thrombectomy for venous thromboembolism (VTE) as a USD 15 billion total addressable market globally, with the U.S. representing nearly $6 billion of that opportunity.

Stryker Corporation (SYK) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies and market dynamics:

1. Product Innovation and Robotic-Assisted Surgery Platforms: A significant driver of revenue growth is expected from continuous product innovation and the expansion of its robotic-assisted surgery platforms, particularly the Mako system. New product launches, such as the expanded Mako software, Surpass Elite stent, LIFEPAK 35, Mako 4, Artix Thrombectomy System, Steri-Shield 8, and Sync Badge, are poised to enhance Stryker's market presence and address evolving healthcare needs. High installation rates of the Mako robotic system and a robust demand for capital equipment contribute significantly to sales growth.

2. Increased Procedural Volumes: Stryker anticipates sustained healthy procedural volumes across its business segments. This continued demand for medical procedures directly benefits sales of implants, robotics, and other capital equipment, underpinning organic revenue growth.

3. Strategic Acquisitions: The company's strategy includes strategic acquisitions to expand its market reach and enhance its portfolio. Recent examples, such as the acquisition of Inari Medical, are aimed at strengthening Stryker's position in high-growth segments like the peripheral vascular market and adding innovative treatment devices. Tuck-in acquisitions are also expected to contribute to revenue.

4. International Expansion and Emerging Markets: Stryker is focusing on greater international contributions, with particular emphasis on growth in emerging markets, as well as specific regions like South Korea and Japan. This geographic expansion allows the company to tap into new customer bases and leverage its global infrastructure.

5. Positive Pricing Impact: Favorable pricing initiatives in both U.S. and international markets, across both MedSurg & Neurotechnology and Orthopaedics segments, are expected to have a positive impact on future revenue growth.

Share Repurchases

• Stryker did not repurchase any shares under its authorized repurchase program in the first three quarters of 2025.
• The total dollar value of shares authorized to be acquired under the share repurchase program was $1,033 million as of March 31, 2025, and September 30, 2025.
• The company previously announced an intention to suspend its share repurchase program through 2021.

Share Issuance

• Stryker issued 1.0 million common stock shares under stock compensation and benefit plans for the nine months ended September 30, 2025.
• In the three months ended March 31, 2025, Stryker issued 0.7 million common stock shares under stock compensation and benefit plans.
• The company issued 5,442 shares of common stock as performance incentive awards to employees in the three months ended March 31, 2021.

Outbound Investments

• Stryker completed the acquisition of Inari Medical, Inc. for approximately $4.9 billion in February 2025, significantly expanding its presence in the high-growth peripheral vascular segment.
• The company acquired Vocera Communications in 2022 to enter the digital care coordination and communications segment.
• In 2021, Stryker acquired TMJ Concepts and OrthoSensor, advancing its offerings in patient-specific joint reconstruction and smart device technologies, respectively.

Capital Expenditures

• Stryker's capital expenditures peaked at $755 million in fiscal year 2024, a notable increase from $575 million in 2023.
• The average capital expenditures for fiscal years 2020 to 2024 amounted to $586 million.
• Capital expenditures are primarily focused on funding ongoing research and development and expanding manufacturing capabilities, with management anticipating a steady hospital capital expenditure environment, particularly benefiting sales of implants, robotics, and capital equipment.